Health
Trump budget draft ends Narcan program and other addiction measures.
The opioid overdose reversal medication commercially known as Narcan saves hundreds of thousands of lives a year and is routinely praised by public health experts for contributing to the continuing drop in opioid-related deaths. But the Trump administration plans to terminate a $56 million annual grant program that distributes doses and trains emergency responders in communities across the country to administer them, according to a draft budget proposal.
In the document, which outlines details of the drastic reorganization and shrinking planned for the Department of Health and Human Services, the grant is among many addiction prevention and treatment programs to be zeroed out.
States and local governments have other resources for obtaining doses of Narcan, which is also known by its generic name, naloxone. One of the main sources, a program of block grants for states to use to pay for various measures to combat opioid addiction, does not appear to have been cut.
But addiction specialists are worried about the symbolic as well as practical implications of shutting down a federal grant designated specifically for naloxone training and distribution.
“Reducing the funding for naloxone and overdose prevention sends the message that we would rather people who use drugs die than get the support they need and deserve,” said Dr. Melody Glenn, an addiction medicine physician and assistant professor at the University of Arizona, who monitors such programs along the state’s southern border.
Neither the Department of Health and Human Services nor the White House’s drug policy office responded to requests for comment.
Although budget decisions are not finalized and could be adjusted, Dr. Glenn and others see the fact that the Trump administration has not even opened applications for new grants as another indication that the programs may be eliminated.
Other addiction-related grants on the chopping block include those offering treatment for pregnant and postpartum women; peer support programs typically run by people who are in recovery; a program called the “youth prevention and recovery initiative”; and programs that develop pain management protocols for emergency departments in lieu of opioids.
The federal health secretary, Robert F. Kennedy Jr., has long shown a passionate interest in addressing the drug crisis and has been outspoken about his own recovery from heroin addiction. The proposed elimination of addiction programs seems at odds with that goal. Last year, Mr. Kennedy’s presidential campaign produced a documentary that outlined federally supported pathways out of addiction.
The grants were awarded through the Substance Abuse and Mental Health Services Administration, an agency within the federal health department that would itself be eliminated under the draft budget proposal, though some of its programs would continue under a new entity, the Administration for a Healthy America.
In 2024, recipients of the naloxone grants, including cities, tribes and nonprofit groups, trained 66,000 police officers, fire fighters and emergency medical responders, and distributed over 282,500 naloxone kits, according to a spokesman for the substance abuse agency.
“Narcan has been kind of a godsend as far as opioid epidemics are concerned, and we certainly are in the middle of one now with fentanyl,” said Donald McNamara, who oversees naloxone procurement and training for the Los Angeles County Sheriff’s Department. “We need this funding source because it’s saving lives every day.”
Matthew Cushman, a fire department paramedic in Raytown, Mo., said that through the naloxone grant program, he had trained thousands of police officers, firefighters and emergency medical responders throughout Kansas City and western rural areas. The program provides trainees with pouches of naloxone to administer in the field plus “leave behind” kits with information about detox and treatment clinics.
In 2023, federal figures started to show that national opioid deaths were finally declining, progress that many public health experts attribute in some measure to wider availability of the drug, which the Food and Drug Administration approved for over-the-counter sales that year.
Tennessee reports that between 2017 and 2024, 103,000 lives saved were directly attributable to naloxone. In Kentucky, which trains and supplies emergency medical workers in 68 rural communities, a health department spokeswoman noted that in 2023, overdose fatalities dropped by nearly 10 percent.
And though the focus of the Trump administration’s Office of National Drug Control Policy is weighted toward border policing and drug prosecutions, its priorities, released in an official statement this month, include the goal of expanding access to “lifesaving opioid overdose reversal medications like naloxone.”
“They immediately reference how much they want to support first responders and naloxone distribution,” said Rachel Winograd, director of the addiction science team at the University of Missouri-St. Louis, who oversees the state’s federally funded naloxone program. “Juxtaposing those statements of support with the proposed eliminations is extremely confusing.”
Mr. Cushman, the paramedic in Missouri, said that ending the naloxone grant program would not only cut off a source of the medication to emergency responders but would also stop classes that do significantly more than teach how to administer it.
His cited the insights offered by his co-instructor, Ray Rath, who is in recovery from heroin and is a certified peer support counselor. In training sessions, Mr. Rath recounts how, after a nasal spray of Narcan yanked him back from a heroin overdose, he found himself on the ground, looking up at police officers and emergency medical responders. They were snickering.
“Ah this junkie again, he’s just going to kill himself; we’re out here for no reason,” he recalled them saying.
Mr. Rath said he speaks with trainees about how the individuals they revive are “people that have an illness.”
“And once we start treating them like people, they feel like people,” he continued. “They feel cared about, and they want to make a change.”
He estimated that during the years he used opioids, naloxone revived him from overdoses at least 10 times. He has been in recovery for five years, a training instructor for the last three. He also works in homeless encampments in Kansas, offering services to people who use drugs. The back of his T-shirt reads: “Hope Dealer.”
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
The sudden death of Kyle Busch has drawn attention to a rare but devastating medical progression: when pneumonia escalates into fatal sepsis.
An ER doctor spoke with Fox News Digital about how sepsis can trigger a rapid health decline.
“Sepsis is actually not a specific disease or diagnosis, but rather the syndrome that occurs when the body has certain abnormal findings and a presumed infection,” said Dr. Kenneth J. Perry, a South Carolina-based emergency medicine physician.
HOW PNEUMONIA PROGRESSES TO SEPSIS: DOCTORS EXPLAIN AFTER KYLE BUSCH’S DEATH
The markers of sepsis include elevated white blood cell counts, a high or low temperature, and elevated heart and respiratory rates, according to Perry. Because of this, a patient with pneumonia is often already technically septic by definition.
In the wake of Kyle Busch’s sudden passing, there is a focus on the rapid decline from pneumonia to fatal sepsis. (Getty; iStock)
While many people assume a worsening infection means bacteria are multiplying uncontrollably, it often has more to do with the body’s internal environment.
“It is often not the bacteria itself that is causing the specific decline,” Perry said. “In most cases, it is a cascade of inflammatory processes that are set in motion by the infection.”
When this inflammation spirals out of control, the body moves from having a manageable infection into severe sepsis. This is when otherwise healthy people can rapidly deteriorate.
SURGE IN WALKING PNEUMONIA AFFECTS THESE HIGH-RISK GROUPS, SAYS DR. MARC SIEGEL
“The concerning thing that can happen with any individual … is that sepsis can then lead to low blood pressure, worsening vital signs and organ damage,” Perry said.
“As multiple organs fail, it becomes very difficult for the medical team to treat and can sometimes lead ultimately to death.”
“The medical evaluation provided to the Busch Family concluded that severe pneumonia progressed into sepsis, resulting in rapid and overwhelming associated complications,” the family shared in a statement. (James Gilbert/Getty Images)
It is very unlikely to have pneumonia and not have any symptoms, according to Perry. Early signs can mimic a severe flu, including fevers, chills, a productive cough, and chest or back pain in cases where the lung is infected.
When sepsis begins to take hold, time becomes the most critical factor. “We have known for a number of years that early antibiotic therapy is beneficial in the treatment of sepsis,” Perry said.
CLICK HERE FOR MORE HEALTH STORIES
If you or a loved one are managing an infection at home, the doctor says the following red flags mean you should bypass the clinic and head straight to the emergency room.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
- Shortness of breath or difficulty breathing
- A racing heart rate or fever that continues to worsen even after starting treatment
- Severe chest pain associated with a productive cough
The slide into sepsis is, in most cases, a cascade of inflammatory processes that are set in motion by the infection, the doctor said. (iStock)
While cases like Busch’s are tragic, Perry stressed that this shouldn’t cause widespread panic. Most patients with pneumonia do very well with standard oral antibiotics.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The NASCAR star’s rapid decline underscores the importance of medical vigilance and “having a primary care physician with whom you have a good relationship,” according to the ER doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Monitoring symptoms while having easy access to primary care is a very beneficial and appropriate plan for most patients,” he added.
NEWYou can now listen to Fox News articles!
Popular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference.
Research led by Cleveland Clinic found that the medications may reduce the spread of several obesity-related cancers, including lung, breast, colorectal and liver cancers.
The findings will be presented at the 2026 ASCO Annual Meeting next week in Chicago.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
According to a press release, the real-world retrospective study included 12,112 patients with the following types of obesity-related cancers, ranging from stage 1 to stage 3.
Popular GLP-1 weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference. (iStock)
- Breast adenocarcinoma
- Prostate adenocarcinoma
- Non-small cell lung cancer (NSCLC)
- Colorectal adenocarcinoma
- Hepatocellular carcinoma (liver cancer)
- Renal cell carcinoma
- Pancreatic adenocarcinoma
Half of the participants started a GLP-1 medication – semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide – after their cancer diagnosis.
The other half began taking a DPP-4 inhibitor comparator “gliptins,” a different class of diabetes medications, the study noted.
WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY
Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers.
The biggest risk reduction was for non-small cell lung cancer (50%), followed by breast cancer (43%), colorectal cancer (31%) and liver cancer (38%).
Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers. (iStock)
“Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,” said lead study author Mark David Orland, MD, of the Taussig Cancer Institute at Cleveland Clinic, in the release. “It provides early evidence that future studies are worth pursuing.”
CLICK HERE FOR MORE HEALTH STORIES
Three other types of cancer – prostate, pancreatic and kidney – also had lower rates of spread among those taking GLP-1s, but those differences were “not statistically significant,” the researchers noted.
“Our study found that use of GLP-1 drugs … was associated with a meaningful reduction in cancer progression across four solid tumor types.”
Tumors with higher levels of GLP-1 receptors — proteins that help cells respond to GLP-1 hormones and drugs — were also linked to better survival outcomes, according to the study findings.
Overall, patients whose tumors had more of these receptors were about one-third less likely to die during the study period.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The incidence of adverse side effects was similar between GLP-1 and gliptin groups.
The findings suggest that GLP-1 pathways may directly influence how some cancers grow or spread, though researchers say more studies are needed to understand the mechanism behind this effect.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The study, which has not yet been peer-reviewed, had some limitations, according to the researchers. As it was retrospective and observational in design – as opposed to a randomized clinical trial – it couldn’t prove that GLP-1 drugs directly prevent cancer progression.
The findings suggest that GLP-1 pathways may directly influence how some cancers grow or spread, though researchers say more studies are needed to understand the mechanism behind this effect. (iStock)
Other factors, such as participants’ health conditions, weight loss and metabolic improvements, may have influenced the results, researchers noted.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
For some specific cancer types, there may not have been enough patients represented to detect statistically significant differences.
Further randomized clinical trials are needed to evaluate these preliminary findings and to determine the specific ways in which GLP-1s control cancer progression.
-
Los Angeles, Ca1 hour agoFamily members searching for 2 missing Southern California girls
-
Detroit, MI2 hours agoDetroit police revise initial account after body cam shows man fatally shot himself during search of home
-
San Francisco, CA2 hours agoSan Francisco rapper Frak blends hip-hop, comedy and Jewish culture
-
Dallas, TX2 hours agoFederal, local agencies tout results of North Texas anti-crime operation before World Cup
-
Boston, MA2 hours agoEast Boston couple accused in alleged racist attack on restaurant patio after calling in noise complaint
-
Denver, CO2 hours agoRep. Hurd emphasizes need for consistent, predictable energy policies at Denver roundtable
-
Seattle, WA2 hours ago
Pollen forensic technique links missing woman cold case to the Pacific Northwest
-
San Diego, CA2 hours agoA South San Diego Mother questions SDPD’S response to her teenage son’s death
